Autologous bone marrow cell transplantation in the treatment of HIV patients with compensated cirrhosis. Issue 6 (23rd June 2020)

• Record Type: Journal Article
• Authors: Liu, Baochi; Cheng, Mingrong; Chen, Xiaodong; Li, Lei; Si, Yanhui; Wang, Shijia; Wang, Ying; Shi, Yufang
• Is Part Of: Bioscience reports. Volume 40:Issue 6(2020)
• Publication Date: 2020-06-23
• Subjects: Autologous bone marrow cell transplantation -- decompensated liver cirrhosis -- human immunodeficiency virus -- stem cell; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20191316
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Liver stem cell therapy is a promising tool to improve decompensated liver cirrhosis (DLC). Especially in patients infected with human immunodeficiency virus (HIV), the condition of the liver may be aggravated by antiretroviral therapy. A total of 21 patients diagnosed with DLC and HIV infection were divided into two groups as follows: those who received (combination therapy group, 14 patients) and those who did not receive (routine therapy group, 7 patients) bone marrow cell transplantation through the portal vein. Two patients died of surgery-related complications in the combination therapy group. The results showed that the survival rate was 85.7% in the combination therapy group after 2 years of follow-up, which was significantly higher than the 14.3% in the conventional therapy group ( P <0.01). After treatment, the liver function score decreased significantly in the combination therapy group at 1 ( t = 4.276, P = 0.000), 3 ( t = 9.153, P = 0.000), and 12 ( t = 13.536, P = 0.000) months, the levels of albumin were significantly increased, and the total bilirubin level and prothrombin time were significantly reduced or shortened as compared with the routine therapy group ( P <0.05 or <0.01). The white blood cell count, hemoglobin, platelet count, and CD4+ and CD8+ levels were significantly higher in the combination therapy group at different time points as compared with the routine therapy group ( P <0.05 or <0.01). In summary, the combination therapy is effective in HIV-infected patients with DLC and useful for the recovery of liver function and cellular immune function but may increase the risk of severe complications after surgery.